Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Projects $28M Loss for 2005 as it Launches $14M Drug-Repositioning Program

NEW YORK, March 17 (GenomeWeb News) - Gene Logic expects to record a loss of between $26 million and $28 million in 2005 as it invests $14 million in a new business initiative designed to help drug makers better select and reposition drug compounds, the company said today.

 

The company also said today that it expects to be profitable in 2007 and generate as much as $100 million. Gene Logic said it expects to generate between $83.5 million and $85.5 million in 2005.

 

However, the company warned that first-quarter revenues would be lower than the year-ago quarter.

 

In  February, the company reported a net loss of 18 percent to $4 million, or $.13 per share, for the quarter ending Dec. 31.

 

Gene Logic said it began its new business plan with a Millennium Pharmaceuticals compound that was removed from clinical trials, and six additional compounds from another undisclosed customer, the company said.

 

Under terms of the agreement, Gene Logic will be paid fees, milestone payments, and royalties for successfully repositioning Millennium's compound, which was discontinued in clinical trials, but not for safety reasons. Gene Logic said it expects to finalize terms for at least two additional repositioning partnerships this year with multiple compounds, for a total of 20 compunds.

 

The company said it expects to spend $14 million through 2007 on the new business initiative, including R&D and SG&A expenditures.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.